Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $32.73.

OTLK has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a research report on Friday, November 29th. Chardan Capital restated a "neutral" rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, BTIG Research dropped their target price on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating for the company in a research report on Friday, November 29th.

Outlook Therapeutics Trading Down 4.8 %

NASDAQ OTLK traded down $0.11 during trading hours on Monday, reaching $2.19. The company had a trading volume of 2,341,891 shares, compared to its average volume of 1,147,958. The stock has a market capitalization of $54.55 million, a P/E ratio of -0.24 and a beta of 0.53. The stock has a 50-day moving average of $2.78 and a 200 day moving average of $5.39. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.06. As a group, sell-side analysts predict that Outlook Therapeutics will post -2.33 EPS for the current year.

Institutional Investors Weigh In On Outlook Therapeutics

A number of hedge funds have recently bought and sold shares of OTLK. Great Point Partners LLC increased its stake in shares of Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock worth $12,557,000 after buying an additional 221,510 shares during the period. Geode Capital Management LLC grew its holdings in Outlook Therapeutics by 49.2% during the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company's stock worth $1,826,000 after acquiring an additional 112,812 shares in the last quarter. State Street Corp increased its position in shares of Outlook Therapeutics by 10.0% in the 3rd quarter. State Street Corp now owns 232,542 shares of the company's stock valued at $1,242,000 after purchasing an additional 21,201 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Outlook Therapeutics by 55.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company's stock valued at $275,000 after purchasing an additional 18,287 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Outlook Therapeutics during the 2nd quarter worth $303,000. Institutional investors and hedge funds own 11.20% of the company's stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.